Search

Your search keyword '"Pusceddu, Sara"' showing total 9 results
Start Over Author "Pusceddu, Sara" Journal cancers
9 results on '"Pusceddu, Sara"'

1. Emerging Treatment Options for Neuroendocrine Neoplasms of Unknown Primary Origin: Current Evidence and Future Perspectives

Author

Corti, Francesca, primary, Rossi, Roberta Elisa, additional, Cafaro, Pietro, additional, Passarella, Gaia, additional, Turla, Antonella, additional, Pusceddu, Sara, additional, Coppa, Jorgelina, additional, Oldani, Simone, additional, Guidi, Alessandro, additional, Longarini, Raffaella, additional, and Cortinovis, Diego Luigi, additional

Published
2024
Full Text
View/download PDF

2. Combined Large Cell Neuroendocrine Carcinomas of the Lung: Integrative Molecular Analysis Identifies Subtypes with Potential Therapeutic Implications

Author

Simbolo, Michele, primary, Centonze, Giovanni, additional, Giudice, Luca, additional, Grillo, Federica, additional, Maisonneuve, Patrick, additional, Gkountakos, Anastasios, additional, Ciaparrone, Chiara, additional, Cattaneo, Laura, additional, Sabella, Giovanna, additional, Giugno, Rosalba, additional, Bossi, Paola, additional, Spaggiari, Paola, additional, Del Gobbo, Alessandro, additional, Ferrero, Stefano, additional, Mastracci, Luca, additional, Fabbri, Alessandra, additional, Filugelli, Martina, additional, Garzone, Giovanna, additional, Prinzi, Natalie, additional, Pusceddu, Sara, additional, Testi, Adele, additional, Monti, Valentina, additional, Rolli, Luigi, additional, Mangogna, Alessandro, additional, Bercich, Luisa, additional, Benvenuti, Mauro Roberto, additional, Bria, Emilio, additional, Pilotto, Sara, additional, Berruti, Alfredo, additional, Pastorino, Ugo, additional, Capella, Carlo, additional, Infante, Maurizio, additional, Milella, Michele, additional, Scarpa, Aldo, additional, and Milione, Massimo, additional

Published
2022
Full Text
View/download PDF

3. Impact of Diabetes and Metformin Use on Enteropancreatic Neuroendocrine Tumors: Post Hoc Analysis of the CLARINET Study

Author

Pusceddu, Sara, primary, Vernieri, Claudio, additional, Di Maio, Massimo, additional, Prinzi, Natalie, additional, Torchio, Martina, additional, Corti, Francesca, additional, Coppa, Jorgelina, additional, Buzzoni, Roberto, additional, Di Bartolomeo, Maria, additional, Milione, Massimo, additional, Regnault, Benjamin, additional, Truong Thanh, Xuan-Mai, additional, Mazzaferro, Vincenzo, additional, and de Braud, Filippo, additional

Published
2021
Full Text
View/download PDF

4. Microwave Ablation Versus Radiofrequency Ablation for Treatment of Hepatocellular Carcinoma: A Meta-Analysis of Randomized Controlled Trials

Author

Facciorusso, Antonio, primary, Abd El Aziz, Mohamed A., additional, Tartaglia, Nicola, additional, Ramai, Daryl, additional, Mohan, Babu P., additional, Cotsoglou, Christian, additional, Pusceddu, Sara, additional, Giacomelli, Luca, additional, Ambrosi, Antonio, additional, and Sacco, Rodolfo, additional

Published
2020
Full Text
View/download PDF

5. Beyond Traditional Morphological Characterization of Lung Neuroendocrine Neoplasms: In Silico Study of Next-Generation Sequencing Mutations Analysis across the Four World Health Organization Defined Groups

Author

Centonze, Giovanni, primary, Biganzoli, Davide, additional, Prinzi, Natalie, additional, Pusceddu, Sara, additional, Mangogna, Alessandro, additional, Tamborini, Elena, additional, Perrone, Federica, additional, Busico, Adele, additional, Lagano, Vincenzo, additional, Cattaneo, Laura, additional, Sozzi, Gabriella, additional, Roz, Luca, additional, Biganzoli, Elia, additional, and Milione, Massimo, additional

Published
2020
Full Text
View/download PDF

7. Comparative Effectiveness of Gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the First-Line Setting of Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis

Author

Pusceddu, Sara, primary, Ghidini, Michele, additional, Torchio, Martina, additional, Corti, Francesca, additional, Tomasello, Gianluca, additional, Niger, Monica, additional, Prinzi, Natalie, additional, Nichetti, Federico, additional, Coinu, Andrea, additional, Di Bartolomeo, Maria, additional, Cabiddu, Mary, additional, Passalacqua, Rodolfo, additional, de Braud, Filippo, additional, and Petrelli, Fausto, additional

Published
2019
Full Text
View/download PDF

9. Impact of Diabetes and Metformin Use on Enteropancreatic Neuroendocrine Tumors: Post Hoc Analysis of the CLARINET Study.

Author

Pusceddu, Sara, Vernieri, Claudio, Di Maio, Massimo, Prinzi, Natalie, Torchio, Martina, Corti, Francesca, Coppa, Jorgelina, Buzzoni, Roberto, Di Bartolomeo, Maria, Milione, Massimo, Regnault, Benjamin, Truong Thanh, Xuan-Mai, Mazzaferro, Vincenzo, and de Braud, Filippo

Subjects
*STATISTICS, *CONFIDENCE intervals, *DIABETES, *TREATMENT effectiveness, *RANDOMIZED controlled trials, *NEUROENDOCRINE tumors, *BLIND experiment, *DESCRIPTIVE statistics, *METFORMIN, *DATA analysis, *STATISTICAL sampling
Abstract

Simple Summary: Lanreotide was found to be effective for preventing tumors from worsening in patients with neuroendocrine tumors of the intestines and pancreas, regardless of whether or not patients also had diabetes. Metformin, a drug for treating diabetes, also seemed to prevent tumors from worsening. The prognostic role of diabetes mellitus (DM) in advanced enteropancreatic neuroendocrine tumors (NETs) is unclear. Progression free survival (PFS) was assessed in post-hoc analyses of the 96-week, phase III, double-blind, placebo-controlled CLARINET study of lanreotide 120 mg in patients with advanced non-functional enteropancreatic NETs with DM (with/without metformin) and without DM. Of 204 patients, there were 79 with DM (lanreotide, n = 42 {metformin, n = 14}; placebo, n = 37 {metformin, n = 10}) and 125 without DM (lanreotide, n = 59; placebo, n = 66). Median PFS was 96.0 and 98.0 weeks with and without DM, respectively (hazard ratio 1.20 {95% confidence interval 0.79 to 1.82}; p = 0.380). No difference in PFS was observed in lanreotide-treated patients with/without DM (p = 0.8476). In the placebo group, median PFS was numerically shorter with versus without DM (p = 0.052) and was significantly longer in patients with DM and metformin (85.7 weeks) versus without metformin (38.7 weeks; p = 0.009). Multivariable Cox analyses showed that DM at baseline was not associated with PFS (p = 0.079); lanreotide was significantly associated with lower disease progression risk (p = 0.017). Lanreotide efficacy was confirmed in patients with advanced enteropancreatic NETs, regardless of diabetic status; DM was not a negative prognostic factor. A potential antitumor effect of metformin was observed in patients receiving placebo. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results